Amphivena is advancing AMV564 in immuno-oncology and developing a portfolio of novel bivalent T cell engagers for the treatment of solid tumors. We are seeking talented and highly motivated individuals with experience in immuno-oncology and biologics drug discovery and development to join the team.  To inquire about open positions, please contact